Saturday, July 11, 2026

Drug profile · INN

remimazolam

remimazolam (BYFAVO) is a gaba-a receptor; anion channel positive allosteric modulator.

EMA: approved NMPA: clinical trials Nervous system (N05) N05CD14
Patents linked 0
Pipeline programs 13
News articles 0
Drug details — remimazolam
Class
Nervous system (N05)
Route
Patents
0
Programs
13
Data quality
0.83

Quick answer

remimazolam (BYFAVO) is a gaba-a receptor; anion channel positive allosteric modulator.

Key facts

INN remimazolam
Brand BYFAVO
Mechanism GABA-A receptor; anion channel positive allosteric modulator
Therapeutic class Nervous system (N05)
ATC code N05CD14

Mechanism of action

GABA-A receptor; anion channel positive allosteric modulator

Approval history

Authority Status Date
EMA approved
NMPA clinical trials

Pipeline programs

  1. Remimazolam Besylate Phase 3 · Chinese Academy of · Analgesia
  2. Remimazolam Besylate Phase 3 · First People's Hospital · Critical Illness; Mechanical Ventilation; Shock
  3. Remimazolam besylate Phase 3 · Chinese Academy of · Sedative
  4. Byfavo 20 mg powder for solution for injection Phase 2 · Disc Medicine · stress anxiety, anxiety
  5. Byfavo Approved · Hospital Authority · Bronchoscopy
  6. Remimazolam Besylate for Injection Approved · First People's Hospital · Thoracic Surgery
  7. Sugammadex hameln /ml oplossing voor injectie for General anesthesia Approved · Disc Medicine · General anesthesia
  8. Remimazolam Unknown · First People's Hospital · Sedation and Analgesia

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. brivaracetam Nervous system (N03)
  4. bupivacaine Nervous system (N01)
  5. buprenorphine Nervous system (N07)
  6. caffeine citrate Nervous system (N06)

Frequently asked questions

What is remimazolam?

remimazolam (BYFAVO) is a gaba-a receptor; anion channel positive allosteric modulator.

What is the brand name for remimazolam?

BYFAVO is a marketed brand name for remimazolam. Check FDA Drugs@FDA for the current US label holder and prescribing information.